Bioavailability of Empagliflozin/Metformin XR FDC vs Free Combination

Phase 1, randomised, open-label trial of empagliflozin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point for Empagliflozin at 72 hours, Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point for Metformin at 72 hours and 2 more. Started Apr 2014; status: completed.